Advanced digestive well-differentiated grade 3 neuroendocrine tumours – ENETS 2020

Prof. Marianne Pavel is the Chair of Endocrinology at the Department of Medicine 1, University of Erlangen, Germany. Board certified as a specialist in internal medicine in 2000 and endocrinology/diabetes in 2001; she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position as an Assistant Director at the Charité University Hospital, Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité University in 2010. In 2009, under her guidance, the NET Center at the Charité University was certified as one of the first ENETS Centers of Excellence. Her major focus in medicine is neuroendocrine tumors for more than 20 years. She has conducted numerous clinical trials in the field of NET. She is involved in the activities from ENETS since 2005 and is first author of the 2012 and the updated 2016 “ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary”. Since April 2014 she is a member of the Executive Committee of ENETS and has recently been elected as chair of ENETS up from 2020. She is involved in scientific and educational activities in NET from different societies including German Cancer Foundation and ESMO.

Dr Teresa Alonso Gordoa is a Medical Oncologist at the Medical Oncology Department of the Hospital Universitario Ramón y Cajal in Madrid. She finalized the degree of medicine by the University of Navarre in 2008 and the medical oncology specialization by the Hospital Universitario Clínico San Carlos in 2013. She is specialized in the care of patients with genitourinary, germ cell and endocrine tumors and in the early drug development unit. In addition, she is a member of the Spanish Society of Medical Oncology (SEOM), the European Society for Medical Oncology (ESMO), the Spanish Society of Genitourinary Oncology (SOGUG), the Germ Cell Group (GG) and the Spanish Group of Neuroendocrine Tumors (GETNE). She participates actively in research projects and clinical trials with international impact. She is a member of the honorary faculty of the University of Alcalá and a reviewer of indexed international journals. She has presented communications in national and international congresses and has participated in the publication of scientific articles in national and international journals.

Dr Teresa Alonso Gordoa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer, BMS, Eusa Pharma, Novartis, Roche, Sanofi Genzyme, Ipsen and Pfizer. 

Dr Jaume Capdevila obtained his medical degree from the University of Lleida, in Catalonia, Spain. In 2000-2001 he held a fellowship in the department of biochemistry and molecular biology at the University of Lleida. From 2002 to 2006 he attended a specialization in medical oncology at the Santa Creu i Sant Pau University Hospital, Barcelona and since 2006 served as medical oncologist at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Since early 2013 he is also leading the gastrointestinal and endocrine tumor unit at Teknon Cancer Institute. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 82 articles in peer-reviewed journals and several book chapters. He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE, and GETHI) and actively participates in national and international trials. He is member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), Secretary and Treasurer of the Spanish Task Force for neuroendocrine tumors (Grupo Español de Tumores Neuroendocrinos, GETNE) and funding member and Treasurer of the Spanish Task Force Group for Research in Orphan and Rare Tumors (Grupo Español de Tumores Huérfanos e Infrecuentes, GETHI). He is also a medical oncologist member of the Thyroid Cancer Working Group within the Spanish Society of Endocrinology and Nutrition (SEEN).

Dr Jaume Capdevila has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, Eisai, Merck, Novartis, Ipsen, Pfizer and Sanofi. 

Biography coming soon.

Dr Jérôme Cros has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Novartis. 

Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.

Dr Angela Lamarca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, EISAI, Merck, Mylan and Delcath, Novartis, Nutricia, Roche, SrtEx and QED. 

 

Prof. Louis de Mestier, MD, PhD, is Full Professor of Gastroenterology at Université Paris-Cité, and serves as a Senior Consultant in the Department of Pancreatology and Digestive Oncology in Beaujon Hospital (APHP, Clichy, France). His main area of clinical expertise, research and teaching is digestive neuroendocrine neoplasms. He conducts clinical and translational research on the clinical and biological heterogeneity of neuroendocrine neoplasms and its therapeutic applications at the INSERM U1149 Research Unit in Paris. He has contributed to more than 170 medical publications, including more than 100 indexed papers in the field of neuroendocrine neoplasms. He is a member of the Advisory Boards of ENETS and GTE.

Prof. Louis de Mestier has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, BMS, Boehringer-Ingelheim, Esteve, Ipsen, Novartis, Mayoly, Servier & Viatris.

Dr Jorge Hernando is a Medical Oncologist at Vall d´Hebron University Hospital in Barelona, Spain. Jorge obtained his MD degree in 2010, and the Specialty in Medical Oncology in 2016 at the Miguel Servet University Hospital in Zaragoza, Spain. In 2017 he obtained his PhD and joined the Gastrointestinal and Endocrine Tumor Unit at Vall d´Hebron University Hospital. He is mainly committed to the clinical management of patients affected by gastrointestinal, neuroendocrine and endocrine malignancies. Jorge is involved in clinical and translational research projects at the Vall d´Hebron Institute of Oncology (VHIO) and he is also coordinator of the gastrointestinal and neuroendorine patient advocacy group. Dr Hernando is involved in professional societies including the American Society of Clinical Oncology (ASCO), European Society for Medical Onology (ESMO), European Neuroendocrine Tumor Society (ENETS) and Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).